JPH0546323B2 - - Google Patents
Info
- Publication number
- JPH0546323B2 JPH0546323B2 JP63038623A JP3862388A JPH0546323B2 JP H0546323 B2 JPH0546323 B2 JP H0546323B2 JP 63038623 A JP63038623 A JP 63038623A JP 3862388 A JP3862388 A JP 3862388A JP H0546323 B2 JPH0546323 B2 JP H0546323B2
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- salt
- antihistamine
- present
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明はヒアルロン酸又その塩と抗ヒスタミン
剤とを含む軟膏剤及び液剤に関し、更に詳しくは
老人性乾皮症、皮膚角化症、軽症のアトピー性皮
膚炎等の治療に有用である軟膏剤及び液剤に関す
る。Detailed Description of the Invention (Field of Industrial Application) The present invention relates to ointments and liquids containing hyaluronic acid or its salts and an antihistamine, and more specifically to senile xeroderma, skin keratosis, and mild atopic dermatitis. The present invention relates to ointments and liquids useful for the treatment of sexual dermatitis, etc.
(従来の技術及び問題点)
従来、住宅環境の整備や都市環境の緑地帯の減
少種々の原因により、冬期の低湿度化が進行する
と共に、人体の皮膚の乾燥状態が進み、特に老人
においては皮膚の老化と共に、低湿度化によつて
老人性乾皮症や皮膚角化症等の症例が増加してい
る。(Prior art and problems) Conventionally, due to various causes such as improvement of housing environment and reduction of green areas in urban environments, the humidity in winter has progressed and the condition of human skin has become dry, especially in the elderly. As the skin ages, cases of senile xeroderma and skin keratosis are increasing due to low humidity.
これらの乾皮症等の対策としては皮膚表面に水
分を十分に補給すると共に、皮膚の水分を保持す
ることが重要であり、これらの目的でプロピレン
グリコール、1,3−ブチレングリコール、ピロ
リドンカルボン酸、ヒアルロン酸等を含む保湿剤
が提供されており、これらの中ではヒアルロン酸
等を含有する外用剤が最も良好なものとして広く
使用されるようになつて来た。 As a countermeasure against xeroderma, etc., it is important to supply sufficient moisture to the skin surface and retain moisture in the skin. For these purposes, propylene glycol, 1,3-butylene glycol, pyrrolidone carboxylic acid Moisturizers containing hyaluronic acid, hyaluronic acid, etc. have been provided, and among these, external preparations containing hyaluronic acid etc. are the most favorable and have come to be widely used.
以上の如き従来の保湿剤は、美容上皮膚の保護
や美化には良い成績を示すものの、前述の如き老
人性乾皮症等の治療には十分な効果を示さず、特
に皮膚の乾燥によつて生じるかゆみ等の問題には
殆ど効果を示さないという問題点があつた。 Although conventional moisturizers such as those mentioned above show good results in cosmetically protecting and beautifying the skin, they are not sufficiently effective in treating conditions such as senile xeroderma as mentioned above. The problem was that it had little effect on problems such as itchiness that may occur.
一方、皮膚のかゆみ等の治療には抗ヒスタミン
剤が一般的に使用されているが、これらの抗ヒス
タミン剤を適用しても皮膚のかゆみは一時的には
抑えられるものの、患部の根本的治療効果は期待
できず、永続的な効果に欠けるという問題があ
る。 On the other hand, antihistamines are commonly used to treat skin itching, etc., but although these antihistamines can temporarily suppress skin itching, they cannot be expected to have a fundamental therapeutic effect on the affected area. However, there is a problem in that it lacks lasting effects.
従つて本発明の目的は、皮膚の保湿剤として有
用であり、特に老人の乾皮症等の治療に有効な外
用薬を提供することである。 Therefore, an object of the present invention is to provide a topical drug that is useful as a skin moisturizer and is particularly effective in treating xeroderma and the like in the elderly.
(問題点を解決するための手段) 以下目的は以下の本発明によつて達成される。(Means for solving problems) The following objects are achieved by the present invention.
すなわち、本発明は、軟膏基材中にヒアルロン
酸又その塩と抗ヒスタミン剤とを配合したことを
特徴とする軟膏剤及び液剤基材中にヒアルロン酸
又その塩と抗ヒスタミン剤とを配合したことを特
徴とする液剤である。 That is, the present invention provides an ointment characterized by blending hyaluronic acid or a salt thereof and an antihistamine in an ointment base material, and an ointment characterized by blending hyaluronic acid or a salt thereof and an antihistamine in a liquid base. It is a liquid agent.
(作用)
軟膏剤や液剤の有効成分としてヒアルロン酸又
その塩と抗ヒスタミン剤とを併用することによつ
て、老人の乾皮症等に対し、十分な保湿剤を与え
ると共に乾皮症特有のかゆみを無くし患部自体の
治療効果が得られる。(Action) By using hyaluronic acid or its salt as an active ingredient in an ointment or liquid together with an antihistamine, it provides a sufficient moisturizer for xeroderma in the elderly, and also relieves the itching characteristic of xeroderma. The effect of treating the affected area itself can be obtained.
(好ましい実施態様)
次に好ましい実施態様を挙げて本発明を更に具
体的に説明する。(Preferred Embodiments) Next, the present invention will be described in more detail by citing preferred embodiments.
本発明において使用するヒアルロン酸又その塩
とは、N−アセチルグルコサミンとD−グルクロ
ン酸を反復構成単位とする複雑な多糖類の1種で
あつて、高い吸水性及び保水性を有し、従来から
化粧品の1成分として使用されており、本発明で
はこれらの公知のヒアルロン酸又その塩がそのま
ま使用できる。 The hyaluronic acid or its salt used in the present invention is a type of complex polysaccharide having N-acetylglucosamine and D-glucuronic acid as repeating constituent units, and has high water absorption and water retention properties. Hyaluronic acid and its salts can be used as they are in the present invention.
又、本発明において上記のヒアルロン酸又その
塩と併用する抗ヒスタミン剤は、ジンマシン、ア
レルギー性鼻炎、胃腸管アレルギー、全身アナフ
イラキシー、皮膚疾患に伴うかゆみ、薬物反応に
よるかゆみ等の治療薬として知られているもので
あつて、例えば、マレイン酸クロルフエニラミ
ン、d−マレイン酸クロルフエニラミン、ジフエ
ンヒドラミン及び塩類、塩酸イソチペンジル、硫
酸クレミゾール、ジフエニールイミダゾール等が
挙げられる。 In addition, the antihistamine used in combination with the above-mentioned hyaluronic acid or its salt in the present invention is known as a treatment for ginma, allergic rhinitis, gastrointestinal tract allergy, systemic anaphylaxis, itching associated with skin diseases, itching due to drug reactions, etc. Examples thereof include chlorpheniramine maleate, d-chlorpheniramine maleate, diphenhydramine and its salts, isothipendyl hydrochloride, clemizole sulfate, diphenylimidazole, and the like.
本発明の軟膏剤及び液剤は上記のヒアルロン酸
又その塩と抗ヒスタミン剤とを軟膏基材や液剤基
材中に溶解又は分散させたことを特徴とするが、
両者の使用割合も重要であつて、例えば、ヒアル
ロン酸又その塩1重量部当り抗ヒスタミン剤を50
乃至200重量部の割合で使用することが好ましく、
ヒアルロン酸又その塩の使用量が少な過ぎると使
用時の保湿性が不足して抗ヒスタミン剤の作用を
十分に発揮させることができない。又、ヒアルロ
ン酸又その塩の使用量が多過ぎても保湿性は十分
であるが、抗ヒスタミン剤の効果が十分でなくな
る。 The ointment and liquid preparation of the present invention are characterized in that the above-mentioned hyaluronic acid or its salt and an antihistamine are dissolved or dispersed in an ointment base material or a liquid base material.
The ratio of use of both is also important; for example, 50 parts of antihistamine per 1 part by weight of hyaluronic acid or its salt.
It is preferable to use it in a proportion of 200 parts by weight.
If the amount of hyaluronic acid or its salt used is too small, the moisturizing properties during use will be insufficient and the effect of the antihistamine agent will not be fully exerted. Furthermore, even if the amount of hyaluronic acid or its salt used is too large, the moisturizing properties will be sufficient, but the effect of the antihistamine will not be sufficient.
本発明において上記ヒアルロン酸又その塩及び
抗ヒスタミン剤を溶解又は分散させる基材は、目
的物が軟膏剤である場合には従来公知の軟膏基材
がそのまま使用でき、例えば、カルボキシメチル
セルロースナトリウム塩、ポリエチレングリコー
ル等の水溶性高分子物、オリーブ油等の植物油、
ワセリン等の鉱物油、セチルアルコール等の低級
アルコール等を主剤とした従来公知のいずれの軟
膏基材も使用できる。特に好ましいものはカルボ
キシメチルセルロースのナトリウム塩である。 In the present invention, when the target product is an ointment, conventionally known ointment base materials can be used as base materials for dissolving or dispersing the above-mentioned hyaluronic acid or its salts and antihistamines, such as carboxymethylcellulose sodium salt, polyethylene glycol, etc. water-soluble polymers such as, vegetable oils such as olive oil,
Any conventionally known ointment base containing mineral oil such as vaseline, lower alcohol such as cetyl alcohol, etc. as a main ingredient can be used. Particularly preferred is the sodium salt of carboxymethyl cellulose.
又、本発明の組成物が液状である場合には、従
来公知のローシヨン基材、液剤の基材等がそのま
ま使用できる。 Further, when the composition of the present invention is in liquid form, conventionally known lotion base materials, liquid agent base materials, etc. can be used as they are.
更に本発明では前記のヒアルロン酸又その塩、
抗ヒスタミン剤及び基材に加えて必要に応じて一
般の薬剤、軟膏剤、液剤等に添加されている各種
の安定剤や保存剤等の添加剤も含有し得るのは当
然である。 Furthermore, in the present invention, the above-mentioned hyaluronic acid or a salt thereof,
It goes without saying that in addition to the antihistamine and the base material, additives such as various stabilizers and preservatives that are added to general medicines, ointments, liquids, etc., may also be contained, if necessary.
本発明の組成物においては、組成物全体に対す
るヒアルロン酸又その塩及び抗ヒスタミン剤の濃
度も重要であり、ヒアルロン酸又その塩は全体を
100重量部とした時に0.01乃至1重量%を占める
割合で使用し、一方、抗ヒスタミン剤は0.5乃至
5重量%を占める割合で使用するのが好ましい。
何れか一方が少な過ぎても多過ぎても両者の相乗
効果は満足できなくなる。 In the composition of the present invention, the concentration of hyaluronic acid or its salt and the antihistamine agent relative to the entire composition is also important;
The antihistamine is preferably used in an amount of 0.01 to 1% by weight based on 100 parts by weight, while the antihistamine is preferably used in an amount of 0.5 to 5% by weight.
If either one is too little or too much, the synergistic effect of the two will not be satisfactory.
(効果)
以上の如き本発明によれば、軟膏剤よ液剤の有
効成分としてヒアルロン酸又その塩と抗ヒスタミ
ン剤とを併用することによつて、老人の乾皮症等
に対し、十分な保湿性を与えると共に乾皮症特有
のかゆみを無くし、患部自体の治療効果が得られ
る。勿論本発明の軟膏及び液剤は乾皮症等の治療
に限定されず、それらの予防や皮膚の美容或いは
荒れ性肌荒れ、かみそり負け、かゆみ等の治療や
予防にも有効である。(Effect) According to the present invention as described above, by using hyaluronic acid or its salt and an antihistamine together as the active ingredients of an ointment or a liquid, sufficient moisturizing properties can be achieved for xeroderma in the elderly. It eliminates the itching characteristic of xeroderma and provides a therapeutic effect on the affected area itself. Of course, the ointments and liquid preparations of the present invention are not limited to the treatment of xeroderma, etc., but are also effective for their prevention, skin beautification, and treatment and prevention of rough skin, razor burn, itching, etc.
(実施例)
次に実施例を挙げて本発明を更に詳しく説明す
る。(Example) Next, the present invention will be explained in more detail with reference to Examples.
実施例 1
ヒアルロン酸又そのナトリウム塩 0.1g
カルボキシメチルセルロースナトリウム塩 2g
マレイン酸クロルフエニラミン 1g
p−ヒドロキシ安息香酸メチル 0.02g
p−ヒドロキシ安息香酸プロピル 0.01g
エタノール 2ml
精製水 全量が100mlになる量
上記処方にて約80mlの精製水にヒアルロン酸又
はそのナトリウム塩及びマレイン酸クロルフエニ
ラミンを加え、又、予めエタノールに溶解してあ
るp−ヒドロキシ安息香酸メチル及びp−ヒドロ
キシ安息香酸プロピルを加えて撹拌し溶解させ
る。溶解後カルボキシメチルセルロースナトリウ
ム塩と残余の水を加え全体をよく混合して均質化
し本発明の軟膏剤を得た。Example 1 Hyaluronic acid or its sodium salt 0.1g Carboxymethylcellulose sodium salt 2g Chlorpheniramine maleate 1g Methyl p-hydroxybenzoate 0.02g Propyl p-hydroxybenzoate 0.01g Ethanol 2ml Purified water Amount to make the total volume 100ml Above According to the prescription, add hyaluronic acid or its sodium salt and chlorpheniramine maleate to approximately 80 ml of purified water, and also add methyl p-hydroxybenzoate and propyl p-hydroxybenzoate that have been dissolved in ethanol in advance. Stir to dissolve. After dissolving, carboxymethylcellulose sodium salt and the remaining water were added and the whole was thoroughly mixed and homogenized to obtain an ointment of the present invention.
比較例 1
実施例1においてヒアルロン酸又はそのナトリ
ウム塩を使用しなかつたことを除き他は実施例1
と同様にして比較例の軟膏剤を得た。Comparative Example 1 Example 1 except that hyaluronic acid or its sodium salt was not used in Example 1.
An ointment of a comparative example was obtained in the same manner as above.
実施例 2
ヒアルロン酸又はそのナトリウム塩 0.1g
マレイン酸クロルフエニラミン 1g
グリセリン 10ml
p−ヒドロキシ安息香酸メチル 0.02g
p−ヒドロキシ安息香酸プロピル 0.01g
エタノール 2ml
精製水 全量が100mlになる量
上記処方にて約80mlの精製水にヒアルロン酸又
はそのナトリウム塩及びマレイン酸クロルフエニ
ラミンを加え、又、予めエタノールに溶解してあ
るp−ヒドロキシ安息香酸メチル及びp−ヒドロ
キシ安息香酸プロピルを加えて撹拌し溶解させ
る。溶解後グリセリン塩と残余の水を加え全体を
よく混合して均質化し本発明の液剤を得た。Example 2 Hyaluronic acid or its sodium salt 0.1g Chlorpheniramine maleate 1g Glycerin 10ml Methyl p-hydroxybenzoate 0.02g Propyl p-hydroxybenzoate 0.01g Ethanol 2ml Purified water Amount to make the total volume 100ml According to the above recipe Add hyaluronic acid or its sodium salt and chlorpheniramine maleate to approximately 80 ml of purified water, and also add methyl p-hydroxybenzoate and propyl p-hydroxybenzoate, which have been previously dissolved in ethanol, and stir to dissolve. let After dissolving, the glycerin salt and the remaining water were added and the whole was thoroughly mixed and homogenized to obtain a liquid preparation of the present invention.
比較例 2
実施例2においてヒアルロン酸又はそのナトリ
ウム塩を使用しなかつたことを除き他は実施例2
と同様にして比較例の液剤を得た。Comparative Example 2 Example 2 except that hyaluronic acid or its sodium salt was not used in Example 2.
A liquid formulation of a comparative example was obtained in the same manner as above.
使用例
実施例及び比較例の軟膏剤及び液剤の63才の老
人の乾皮症部分に約5g/m2の割合で薄く塗布
し、塗布後5日間の経過を見たところ、次ぎの如
き結果を得た。Usage Example When the ointments and liquids of Examples and Comparative Examples were thinly applied to the dry skin area of a 63-year-old elderly man at a rate of approximately 5 g/m 2 and the progress was observed for 5 days after application, the following results were obtained. I got it.
実施例1:皮膚の乾燥や痒感が著明に抑制さ
れ、従来抗ヒスタミン剤ではあまり効果が期待
できない丘疹や紅班に対しても明かな治療効果
が認められた。又、患者は痒感による精神的
なストレスからも著明に開放された。従つてヒ
アルロン酸又はその塩を抗ヒスタミン剤に併用
することによつて、従来の抗ヒスタミン剤の効
果が数倍(2乃至3倍)にも増強された。Example 1: Skin dryness and itching were significantly suppressed, and a clear therapeutic effect was observed on papules and erythema, for which conventional antihistamines are not expected to be very effective. In addition, the patient was significantly relieved from the mental stress caused by the itching sensation. Therefore, by using hyaluronic acid or a salt thereof in combination with an antihistamine, the effect of conventional antihistamines was enhanced several times (2 to 3 times).
実施例2:実施例1と同様な効果を奏し、更に夏
期の使用においてはさつぱりとした使用感があ
つた。Example 2: The same effect as in Example 1 was obtained, and the product also had a refreshing feeling when used in summer.
比較例1: 痒感の抑制効果は有るが、実施例
に比較してその抑制効果は約半分程度であつ
た。又、皮膚の乾燥が止まらず、部位によつて
は皮膚表面に亀裂が生じて悪化した。又、丘疹
や紅班に対しては殆ど効果が無かつた。Comparative Example 1: Although there was an effect of suppressing itching sensation, the suppressive effect was about half that of the example. In addition, the dryness of the skin did not stop, and cracks appeared on the skin surface in some areas, which worsened the situation. Furthermore, it had almost no effect on papules and erythema.
比較例2:比較例1と同様であつた。Comparative Example 2: Same as Comparative Example 1.
以上の通り本発明によれば、ヒアルロン酸単独
又は抗ヒスタミン剤単独のいずれによつても得ら
れない優れた相乗効果が得られる。 As described above, according to the present invention, an excellent synergistic effect that cannot be obtained with either hyaluronic acid or antihistamine alone can be obtained.
Claims (1)
タミン剤とを配合したことを特徴とする軟膏剤。 2 液剤基材中にヒアルロン酸又その塩と抗ヒス
タミン剤とを配合したことを特徴とする液剤。[Scope of Claims] 1. An ointment characterized by containing hyaluronic acid or its salt and an antihistamine in an ointment base material. 2. A liquid agent characterized by containing hyaluronic acid or its salt and an antihistamine agent in a liquid agent base material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3862388A JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3862388A JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01213227A JPH01213227A (en) | 1989-08-28 |
| JPH0546323B2 true JPH0546323B2 (en) | 1993-07-13 |
Family
ID=12530366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3862388A Granted JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01213227A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2621877B1 (en) * | 2016-01-04 | 2018-05-04 | Agencia Pública Empresarial Sanitaria Hospital De Poniente | SOLUTION FOR ENDOSCOPIC RESECTION |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (en) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Topical compsn. contg. hyaluronic acid deriv. as vehicle |
| JPS61207310A (en) * | 1985-03-11 | 1986-09-13 | Shiseido Co Ltd | External agent for skin |
| JPS6245336A (en) * | 1985-08-21 | 1987-02-27 | Toyo Biyuut Kk | Emulsified composition |
| JPS62110722A (en) * | 1985-11-06 | 1987-05-21 | Nippon Denso Co Ltd | Air cleaner for internal combustion engine |
-
1988
- 1988-02-23 JP JP3862388A patent/JPH01213227A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01213227A (en) | 1989-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4133837B2 (en) | Skin moisturizing gel and method | |
| DE69733086T2 (en) | PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN KUUU NUTS OIL | |
| US5002760A (en) | Retinol skin care composition | |
| CN100496579C (en) | Antipruritic compositions and compositions for wound healing | |
| US6096326A (en) | Skin care compositions and use | |
| US5447930A (en) | Topical anesthetic compositions | |
| JP2000319187A (en) | Carbon dioxide transcutaneous and transmucosal absorption composition | |
| JPH0215023A (en) | Anesthetic/skin humidifying composition and production thereof | |
| JP2015530380A (en) | Composition for treating psoriasis | |
| JPH027287B2 (en) | ||
| JPH09157172A (en) | Topical skin and eczema | |
| CN1280495A (en) | Use of a mixture of a diol and an alpha-hydroxy acid for treatment of hyperkeratotic skin diseases | |
| US5176918A (en) | Topical medicament | |
| RU2430716C2 (en) | Anhydrous dermatological or cosmetic ureal preparation | |
| US20080076831A1 (en) | Hemorrhoid reliever and method of use | |
| JP2000038352A (en) | External composition | |
| CA2285012C (en) | Remedy for external application, and use of an oil-in-water emulsion for said remedy | |
| JPH0546323B2 (en) | ||
| JP3479048B2 (en) | Cosmetics and non-woven fabric impregnated cosmetics | |
| JP2001097848A (en) | Preparation composition for external use | |
| JP5170973B2 (en) | Topical skin preparation | |
| JP2000229884A (en) | External preparation for skin | |
| JPH11246329A (en) | Skin preparation for external use | |
| JP3723728B2 (en) | Skin topical solution | |
| JPH08165244A (en) | Skin disease treatment |